Brachyury Protein Targets Chordoma
This is a news story, published by Guardian, that relates primarily to Workman news.
Workman news
For more Workman news, you can click here:
more Workman newsdisease research news
For more disease research news, you can click here:
more disease research newsGuardian news
For more news from Guardian, you can click here:
more news from GuardianAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
chordoma cancer cells. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Cancer Drug Discovery news, protein brachyury news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Cancer ResearchGuardian
•Health
Health
British professor makes ‘thrilling’ breakthrough for cancer that killed his mother

78% Informative
Professor Paul Workman 's mother, Ena , died of a rare bone cancer known as chordoma.
About one in a million people are affected by the condition, which is untreatable.
Workman and his colleagues pinpointed a key protein, known as brachyury, which they realised was crucial to the survival of chordoma cancer cells in a patient’s body.
The discovery caused great excitement among researchers because it suggested a route for attacking chordoma: block the protein brachury and this would damage cancer cells whose growth it was promoting.
Process known as crystallographic fragment screening played a crucial role in highlighting sites where drugs could best latch on to the brachyury protein.
However, Workman stressed that more research was still needed to perfect a drug that would be effective in treating chordoma.
“We need to begin trials in chordoma cell lines first and then in chordomas models in animals before we start trials in humans. That could take five years to complete. Then, hopefully, we will finally be ready to tackle the challenge of chordoma.”.
VR Score
79
Informative language
79
Neutral language
59
Article tone
informal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links